Research Progress of Tislelizumab-Induced Immune-Related Adverse Events
Objective To provide a reference for the safe use of tislelizumab in clinical practice.Methods More than 30 literature such as clinical studies on the safety of tislelizumab and case reports of adverse reactions after its marketing in the CNKI,VIP,WanFang,CBM,PubMed,Embase,Web of Science and others from the inception of these databases to April 30,2023 were searched to systematically summarize the characteristics of tislelizumab-induced immune-related adverse events(irAEs).Results In different clinical trials,the total incidence of tislelizumab-induced irAEs was in the range of 22.2%to 76.7%,with the incidence of irAEs≥grade three in the range of 7.0%to 36.7%.Tislelizumab-induced irAEs commonly occured in the skin system,endocrine system,digestive system,urinary system,respiratory system,cardiovascular system,and clinical manifestations included rash,thyroid dysfunction,hyperglycemia,diarrhea,renal function damage,pneumonia,cardiomyopathy and so on.The current clinical observations and related studies showed that the tislelizumab-induced irAEs were mostly mild and did not lead to treatment interruption.Conclusion The occurrence of irAEs indicates that tislelizumab has a certain safety in the clinical application for malignant tumor treatment.However,as a newly marketed drug,the clinical application time of tislelizumab is short,and clinical physicians have limited experience in its application.It is suggested that clinical physicians should pay more attention to the indication control and medication monitoring to ensure the medication safety.
tislelizumabimmune-related adverse eventmalignant tumoradverse drug reactionsafety evaluation
万方数据
维普
